MENVEO (Vaccines against invasive meningococcal disease, serogroups A, C, W, Y and B) - Invasive meningococcal disease serogroups A, C, W-135
Reason for request
Summary of opinion
Favourable opinion for extension of reimbursement in the active immunisation of individuals against invasive meningococcal di-sease caused by Neisseria meningitidis serogroups A, C, W-135, Y and B, in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025.
Clinical Benefit
| Substantial |
The update to the vaccine strategy in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025 is not of a nature to modify the clinical benefit, which remains substantial in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W, Y and B. |
Clinical Added Value
| Unspecified |
The update to the vaccine strategy in accordance with the current HAS recommendations of 13/03/2025 and 17/07/2025 is not of a nature to modify the Transparency Committee’s previous conclusions. |
